Select Bibliography

Filter by any of these (after searching):

Hoke, Eva

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 9 items

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017

Manuscript - Primary - Primary - Leukemia - CALGB-10503

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018

Manuscript - Primary - Primary - Leukemia - CALGB-10404

Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission

Kolitz, Jonathan E. , George, Stephen L. , Benson, Don M. ... - - Cancer - 2014

Manuscript - Primary - Long-Term-Followup - Leukemia - CALGB-19808

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Kolitz, Jonathan E. , George, Stephen L. , Marcucci, Guido ... - - Blood - 2010

Manuscript - Primary - Primary - Leukemia - CALGB-19808 , CALGB-8461

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Lin, Thomas S. , Donohue, Kathleen A. , Byrd, John C. ... - - J Clin Oncol - 2010

Manuscript - Primary - Primary - Leukemia - CALGB-10101

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002

Rizzieri, David A. , Johnson, Jeffrey L. , Byrd, John C. ... - - Br J Haematol - 2014

Manuscript - Primary - Primary - Leukemia - CALGB-10002

CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)

Vij, Ravi , Hars, Vera , Blum, William , Shore, Tsiporah ... - EBMT - Bone Marrow Transplantation - 2015

Abstract - Primary - Primary - Transplant - CALGB-100801

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Voorhees, Peter M. , Mulkey, Flora , Hassoun, Hani ... - ASH - Blood - 2015

Abstract - Primary - Preliminary - Myeloma - Alliance-A061202

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

Wetzler, Meir , Watson, Dorothy , Stock, Wendy , Koval, Gregory ... - - Haematologica - 2014

Manuscript - Primary - Primary - Leukemia - CALGB-10001